Nektar Therapeutics - Common Stock (NQ:NKTR)

43.58 UNCHANGED

Delayed Quote Updated: 4:15 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

March 06, 2026

From Robbins LLP

Via Business Wire

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

Via Finterra

Topics Lawsuit

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Via Stocktwits

Topics Stocks

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts ↗

February 11, 2026

The company reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of the trial.

Via Stocktwits

Top stock movements in today's session. ↗

February 10, 2026

Via Chartmill

Here are the top movers in Tuesday's session. ↗

February 10, 2026

Via Chartmill

These stocks are gapping in today's session ↗

February 10, 2026

Via Chartmill

Top movers in Tuesday's pre-market session ↗

February 10, 2026

Via Chartmill

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗

February 10, 2026

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗

January 05, 2026

There is a key difference between these two biotechs.

Via The Motley Fool

Topics Bankruptcy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗

December 28, 2025

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

Via The Motley Fool

Topics Regulatory Compliance

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗

December 28, 2025

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Via The Motley Fool

Topics Regulatory Compliance

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Via The Motley Fool

Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher ↗

November 06, 2025

Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading.

Via Chartmill

This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street ↗

October 13, 2025

Is it too late to get on the bandwagon?

Via The Motley Fool

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗

October 05, 2025

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 03, 2025

Via Benzinga

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗

September 21, 2025

Here's what needs to happen for these high flyers to continue soaring.

Via The Motley Fool

Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today ↗

September 18, 2025

One of the company's pipeline drugs is showing significant promise.

Via The Motley Fool

Why Is Nektar Therapeutics Stock Trading Lower On Thursday? ↗

September 18, 2025

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

Via Benzinga

Why Nektar Therapeutics Rippled Higher This Week ↗

September 05, 2025

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Via The Motley Fool

Topics Intellectual Property

What's Going On With Nektar Therapeutics Stock On Thursday? ↗

September 04, 2025

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 04, 2025

Via Benzinga

Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗

September 04, 2025

Via Benzinga

Why Nektar Therapeutics Stock Popped 6% on Friday ↗

August 08, 2025

The company said it has sufficient financial resources to fund its operations into early 2027.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.